These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6872549)

  • 21. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.
    Gleerup G; Persson B; Hedner T; Winther K
    Eur J Clin Pharmacol; 1993; 44(2):121-5. PubMed ID: 8453957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
    McBride PA; Mann JJ; Nimchinsky E; Cohen ML
    Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.
    Demoulin JC; Bertholet M; Soumagne D; David JL; Kulbertus HE
    Lancet; 1981 May; 1(8231):1186-8. PubMed ID: 6112531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of ketanserin on hemostasis in vitro.
    Bergqvist D; Arvidsson S; Haglund U; Hedner U; Lindblad B
    Thromb Res; 1986 Jul; 43(2):237-41. PubMed ID: 2943051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of serotonin inhibition in air embolism in dogs.
    Vincent JL; Goldstein J; Domb M; Lignan H
    Eur Surg Res; 1988; 20(3):175-80. PubMed ID: 3402512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries.
    Bush LR
    J Pharmacol Exp Ther; 1987 Feb; 240(2):674-82. PubMed ID: 3806419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there alpha-adrenergic blockade and/or serotonergic blockade during chronic ketanserin treatment?
    Ball SG; Robertson JI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S120-2. PubMed ID: 2412031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haemodynamic effects of ketanserin either alone or with oxygen in COPD patients with secondary pulmonary hypertension.
    Domenighetti G; Leuenberger P; Feihl F
    Monaldi Arch Chest Dis; 1997 Oct; 52(5):429-33. PubMed ID: 9510660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of ketanserin on central haemodynamics and coronary circulation.
    Hood S; Birnie D; Nasser A; Hillis WS
    J Cardiovasc Pharmacol; 1998 Dec; 32(6):983-7. PubMed ID: 9869505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin.
    Dzúrik R; Fetkovská N; Brimichová G; Tison P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S29-31. PubMed ID: 2412052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
    Buczko W; Gambino MC; De Gaetano G
    Eur J Pharmacol; 1984 Aug; 103(3-4):261-8. PubMed ID: 6237923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of ketanserin, a specific serotonin antagonist, on burn shock hemodynamic parameters in a porcine burn model.
    Holliman CJ; Meuleman TR; Larsen KR; Port JD; Stanley TH; Pace NL; Warden GD
    J Trauma; 1983 Oct; 23(10):867-71. PubMed ID: 6632010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs.
    Fletcher JR; Ramwell PW
    Circ Shock; 1980; 7(3):299-308. PubMed ID: 7004660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    Agents Actions; 1985 Jul; 16(5):313-7. PubMed ID: 2931964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonism by ketanserin of 5-HT-induced vasoconstriction unmasks a 5-HT-induced vasodilation.
    McLennan PL; Taylor DA
    Eur J Pharmacol; 1984 Sep; 104(3-4):313-8. PubMed ID: 6499925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous inhibition of serotonin-induced platelet aggregation during chronic ketanserin administration to man can be detected after plasma pH control.
    Arnout J; van Russelt M; Deckmyn H; Vermylen J
    Haemostasis; 1987; 17(6):344-8. PubMed ID: 3428721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of serotonin in patients with acute respiratory failure.
    Huval WV; Lelcuk S; Shepro D; Hechtman HB
    Ann Surg; 1984 Aug; 200(2):166-72. PubMed ID: 6547816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine.
    McGoon MD; Vanhoutte PM
    J Clin Invest; 1984 Sep; 74(3):828-33. PubMed ID: 6470141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.